Sellas’ cancer vaccine extends survival in blood cancer trial, company says
The Hindu — Health · 19 Nov 2026 · 1 min read
Sellas Life Sciences said on Tuesday, November 17, 2026 that its experimental vaccine helped patients with a type of blood cancer live longer in a late-stage trial.
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow.
Patients who received GPS lived a median of 24 months, compared to 14.7 months for those given the best available treatment, Sellas said.
The company plans to talk to the U.
S.
Food and Drug Administration about seeking approval for the vaccine. Its shares were halted in premarket trading.
Related articles
India · The Hindu — Health · 16 hours agoWhy data interoperability is critical to the future of hospital care
The future of critical care will be defined by how effectively the information is connected, interpreted and applied
Read full article
India · The Hindu — Health · 23 hours agoIndia missed its 2025 TB elimination target. What does the WHO report show?
The WHO’s Global Tuberculosis Report 2026 has withheld India’s 2025 incidence estimate pending an assessment of new surveillance data. What does the report reveal…
Read full article
India · The Hindu — Health · 1 day agoHyderabad doctor brings down rare disease drug cost from ₹9 crore to ₹2.5 lakh; seven children to get free treatment
Seven children diagnosed with Allan-Herndon-Dudley syndrome (AHDS), a rare genetic disorder, are set to receive a year’s supply of the medicine tiratricol free of…
Read full article